Trial Profile
Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard(R) 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2015
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms AFU-GETUG20
- Sponsors UNICANCER
- 09 Jul 2014 New trial record